Study of two targeted pills for EGFR-mutated lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new combination of two oral targeted drugs for people with advanced non-small cell lung cancer that has an EGFR mutation. It may help if you have already been treated with a third-generation EGFR pill or if you are starting treatment for the first time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have a type of lung cancer called non-squamous non-small cell lung cancer that has spread and cannot be cured with surgery.
- You need to have a specific EGFR gene change in your tumor (certain types are required for different parts of the study).
- You must have had prior treatment with a third-generation EGFR pill, or if you haven't had any treatment yet, you may be eligible for a specific group in this study.
- You should be in good physical condition (able to do your daily activities without help) and have stable brain metastases if they are present.
- You must be willing to provide tumor and blood samples for testing.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two targeted therapy pills, aumolertinib and osimertinib, for people with a specific EGFR mutation in advanced non-small-cell lung cancer that has spread. Both drugs are designed to block cancer growth signals. The study aims to see which one works better as a first treatment.
This study tests an oral pill (DZD9008) that targets a specific genetic change in lung cancer called EGFR. If you have this mutation, the drug may shrink your tumor or slow its growth, especially if other treatments have stopped working or caused side effects.
This trial tests a combination of two targeted pills (sunvozertinib and anlotinib) as a first treatment for people with advanced lung cancer that has a specific EGFR mutation. It aims to see if this combination works better than current standard treatments.
This trial tests an oral drug called DZD6008 for people with advanced non-small cell lung cancer (NSCLC) that has certain EGFR mutations. It may be an option for those who have tried other EGFR treatments or are new to treatment.
This trial tests a combination of two targeted drugs (DZD9008 and AZD4205) for people with advanced non-small cell lung cancer that has a specific EGFR mutation and has stopped responding to standard treatments. The goal is to see if this combination can shrink tumors or slow cancer growth.
This study tests a new pill called sunvozertinib in people with advanced non-small cell lung cancer that has a specific EGFR mutation and has stopped responding to earlier treatments. The goal is to see how well it works and if it is safe.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.